iVexSol is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made. Its technology will greatly reduce the complexity, cost, and development time of these critical reagents, thereby accelerating the development and enabling greater access to life-changing cell and gene therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/01/20 | $13,000,000 | Series A |
BioLife Solutions Casdin Capital | undisclosed |
| 01/26/23 | $23,800,000 | Series A-3 |
Asahi Kasei BioLife Solutions Bristol Myers Squibb Casdin Capital Charles River Laboratories | undisclosed |
